Loading...
XNAS
SEER
Market cap104mUSD
Dec 05, Last price  
1.88USD
1D
-2.08%
1Q
-10.48%
IPO
-96.91%
Name

Seer Inc

Chart & Performance

D1W1MN
XNAS:SEER chart
P/E
P/S
7.52
EPS
Div Yield, %
Shrs. gr., 5y
0.47%
Rev. gr., 5y
199.37%
Revenues
14m
-8.13%
058,000656,0006,394,00014,685,00015,182,00013,947,000
Net income
-87m
L+0.37%
-6,307,000-16,043,000-31,169,000-68,633,000-88,697,000-86,277,000-86,599,000
CFO
-46m
L-21.94%
-4,651,000-13,073,000-20,828,000-46,347,000-60,780,000-59,065,000-46,109,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
IPO date
Dec 04, 2020
Employees
164
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT